Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 9/2/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Scott E. Simonet

Wrong Dr. Scott E. Simonet?

Vice President

Phone: (805) ***-****  
Amgen Inc.
One Amgen Center Drive
Thousand Oaks , California 91320
United States

Company Description: Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It...   more

Employment History


  • Ph.D.
  • Ph.D
27 Total References
Web References
BIT's 9th Annual Congress of International Drug Discovery Science and Technology, 3 Mar 2011 [cached]
Dr. Scott Simonet, Vice President, Metabolic Disorders Therapeutic Area, Amgen, USA
Dr.Scott Simonet, Vice President, Metabolic Disorders Research, Amgen, USA
Osteoporosis: People, 30 July 2005 [cached]
Scott Simonet, Ph.D., Director, Research Department of Metabolic Disorders
Scott Simonet, Ph.D.
Scott Simonet, Ph.D.Director, Research Department of Metabolic Disorders Bone and Mineral MetabolismAmgen
Scott received his Ph.D. in Molecular Biology and Biochemistry from the University of South Florida, College of Medicine in 1988.He subsequently received an Individual National Research Service Award from the NIH to perform postdoctoral training at the Gladstone Foundation Laboratories for Cardiovascular Disease at the University of California, San Francisco, where he studied regulation of apolipoprotein gene expression with John Taylor and Bob Mahley.
Scott came to Amgen as a Research Scientist in February of 1992 and began to search for secreted proteins, which might have therapeutic utility.In 1994 he was part of a group contributing to Amgen's Genomics program that identified and determined the function of a secreted protein in the TNFR Superfamily called osteoprotegerin (OPG).This group showed that OPG was a critical regulator of bone mineral density and acts by inhibiting the actions of RANKL on osteoclastogenesis.In 1998, this work received an award from the American Society of Bone and Mineral Research for Outstanding Research on the Pathophysiology of Osteoporosis.
Scott is currently Director of the Bone and Mineral Metabolism Research group in the Department of Metabolic Disorders at Amgen.He heads a group of 33 scientists working on developing novel therapies for osteoporosis and other bone related diseases.
W. Scott Simonet, ..., 23 Dec 2013 [cached]
W. Scott Simonet, Ph.D.
Vice President, Research Department of Metabolic Disorders Amgen
BIT's 10th Annual Congress of International Drug Discovery Science and Technology, 2 Feb 2013 [cached]
Dr. Scott Simonet, Vice President, Metabolic Disorders Therapeutic Area, Amgen, USA
Amgen - Media - Feature - Amgen Scientists Recognized for “Most-Cited” Paper on Osteoclast Differentiation, 9 April 2009 [cached]
The authors, William J. Boyle, Scott Simonet and David Lacey, worked together at Amgen in the 1990s.
Lacey is now senior vice president of Research at Amgen and Simonet is executive director of Research in the area of Metabolic Disorders at Amgen.
Amgen's Scott Simonet.
Other People with the name "Simonet":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.